PMDA drug package insert
スキリージ皮下注150mgシリンジ1mL
PMDA Prescription drug · アッヴィ合同会社 · package insert Sep 16, 2026
Key facts
| Brand names | スキリージ皮下注150mgシリンジ1mL, スキリージ皮下注75mgシリンジ0.83mL, スキリージ皮下注55mgシリンジ0.37mL, スキリージ皮下注150mgペン1mL |
|---|---|
| Nonproprietary names | リサンキズマブ（遺伝子組換え） |
| Companies | 製造販売元／アッヴィ合同会社 |
| Product type | Prescription drug |
| Therapeutic category | ヒト化抗ヒトIL-23p19モノクローナル抗体製剤 |
| Therapeutic category codes | 873999 |
| YJ codes | 3999450G2024, 3999450G1028, 39994C9G6023, 3999450G3020 |
| Approval numbers | 30300AMX00456000, 23100AMX00299000, 30800AMX00327000, 30300AMX00457000 |
| Package insert edition | 第6版 |
| Package insert date | Sep 16, 2026 |
| PMDA document key | 112130_3999450G1028_1 |
| PMDA company code | 112130 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- Yes Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: